Technical Analysis for RETA - Reata Pharmaceuticals, Inc. - Class A

Grade Last Price % Change Price Change
grade C 156.12 -1.19% -1.88
RETA closed down 1.19 percent on Thursday, July 9, 2020, on 45 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical RETA trend table...

Date Alert Name Type % Chg
Multiple of Ten Bearish Other 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish -1.19%
Oversold Stochastic Weakness -1.19%
Fell Below 20 DMA Bearish 0.31%
Multiple of Ten Bearish Other 0.31%
Outside Day Range Expansion 0.31%
Oversold Stochastic Weakness 0.31%
20 DMA Support Bullish -2.69%
Multiple of Ten Bullish Other -2.69%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Medicine Diseases Inflammation Health Care Pulmonary Arterial Hypertension Pulmonary Hypertension Friedreich's Ataxia Interstitial Lung Disease Myopathy

Is RETA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 257.965
52 Week Low 70.0
Average Volume 383,585
200-Day Moving Average 172.98
50-Day Moving Average 155.06
20-Day Moving Average 162.24
10-Day Moving Average 158.16
Average True Range 8.45
ADX 21.94
+DI 26.16
-DI 18.85
Chandelier Exit (Long, 3 ATRs ) 157.98
Chandelier Exit (Short, 3 ATRs ) 154.26
Upper Bollinger Band 175.20
Lower Bollinger Band 149.29
Percent B (%b) 0.26
BandWidth 15.97
MACD Line 1.06
MACD Signal Line 2.07
MACD Histogram -1.0166
Fundamentals Value
Market Cap 4.08 Billion
Num Shares 26.1 Million
EPS -1.06
Price-to-Earnings (P/E) Ratio -147.28
Price-to-Sales 15.55
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 163.64
Resistance 3 (R3) 164.27 162.38 162.39
Resistance 2 (R2) 162.38 160.47 162.07 161.97
Resistance 1 (R1) 159.25 159.28 158.31 158.63 161.55
Pivot Point 157.37 157.37 156.90 157.06 157.37
Support 1 (S1) 154.24 155.45 153.30 153.61 150.69
Support 2 (S2) 152.35 154.27 152.04 150.27
Support 3 (S3) 149.22 152.35 149.85
Support 4 (S4) 148.60